JP6250542B2 - エクトインの治療的使用 - Google Patents

エクトインの治療的使用 Download PDF

Info

Publication number
JP6250542B2
JP6250542B2 JP2014528897A JP2014528897A JP6250542B2 JP 6250542 B2 JP6250542 B2 JP 6250542B2 JP 2014528897 A JP2014528897 A JP 2014528897A JP 2014528897 A JP2014528897 A JP 2014528897A JP 6250542 B2 JP6250542 B2 JP 6250542B2
Authority
JP
Japan
Prior art keywords
composition
ectoine
inflammation
cells
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014528897A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014526448A5 (enExample
JP2014526448A (ja
Inventor
ウンフリード，クラウス
シドリク，ウルリヒ
クルトマン，ジーン
ビルシュタイン，アンドレーアス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bitop AG
Original Assignee
Bitop AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bitop AG filed Critical Bitop AG
Publication of JP2014526448A publication Critical patent/JP2014526448A/ja
Publication of JP2014526448A5 publication Critical patent/JP2014526448A5/ja
Application granted granted Critical
Publication of JP6250542B2 publication Critical patent/JP6250542B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2014528897A 2011-09-09 2012-09-07 エクトインの治療的使用 Active JP6250542B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011113059A DE102011113059A1 (de) 2011-09-09 2011-09-09 Therapeutische Anwendungen von Ectoin
DE102011113059.8 2011-09-09
PCT/EP2012/003757 WO2013034299A1 (de) 2011-09-09 2012-09-07 Therapeutische anwendungen von ectoin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017133770A Division JP6396544B2 (ja) 2011-09-09 2017-07-07 エクトインの治療的使用

Publications (3)

Publication Number Publication Date
JP2014526448A JP2014526448A (ja) 2014-10-06
JP2014526448A5 JP2014526448A5 (enExample) 2015-11-05
JP6250542B2 true JP6250542B2 (ja) 2017-12-20

Family

ID=47115708

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014528897A Active JP6250542B2 (ja) 2011-09-09 2012-09-07 エクトインの治療的使用
JP2017133770A Active JP6396544B2 (ja) 2011-09-09 2017-07-07 エクトインの治療的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017133770A Active JP6396544B2 (ja) 2011-09-09 2017-07-07 エクトインの治療的使用

Country Status (12)

Country Link
US (1) US20140315869A1 (enExample)
EP (2) EP2753330B1 (enExample)
JP (2) JP6250542B2 (enExample)
CN (1) CN103857394A (enExample)
BR (1) BR112014005414A2 (enExample)
CA (1) CA2848010A1 (enExample)
DE (1) DE102011113059A1 (enExample)
ES (2) ES2657907T3 (enExample)
IN (1) IN2014CN02458A (enExample)
PL (2) PL2753330T3 (enExample)
RU (1) RU2648475C2 (enExample)
WO (1) WO2013034299A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160106747A1 (en) * 2008-01-30 2016-04-21 Bitop Ag Treating postoperative mechanical stress with an ectoine
DE102008039231A1 (de) 2008-08-22 2010-02-25 Bitop Ag Verwendung von Glucosylglycerol
DE102014007423A1 (de) * 2014-05-22 2015-11-26 Bitop Ag Zusammensetzung zur Behandlung des Auges
DE102014113781A1 (de) * 2014-09-23 2016-03-24 Bitop Ag Solut und Solutgemisch sowie eine Zusammensetzung enthaltend mindestens ein Solut zur Verwendung bei der Prävention oder Behandlung von durch Schwebstaub verursachter kosmetischer oder pathologischer Effloreszenzen
DE102015121050A1 (de) * 2015-12-03 2017-06-08 Bitop Ag Kompatibles Solut oder Solutgemisch zur Verwendung bei der Prävention oder Behandlung von Krankheiten mit Barrieredefekten in Epithelgeweben
DE102016104470A1 (de) 2016-03-11 2017-09-14 Bitop Ag Zusammensetzung zur Förderung der Aktivität von Sirtuinen
CN111936142A (zh) * 2018-04-05 2020-11-13 株式会社资生堂 Asmt表达促进剂
CN114425056A (zh) * 2020-10-14 2022-05-03 宁波希诺赛生物科技有限公司 一种用于改善哮喘的干细胞外泌体组合物
CN116570525B (zh) * 2023-06-30 2025-09-23 华熙生物科技股份有限公司 一种具有舒缓功效的组合物及其制备方法和用途
PL448505A1 (pl) * 2024-05-08 2025-11-12 Szkoła Główna Gospodarstwa Wiejskiego w Warszawie Kompozycja o właściwościach barierowych i wirusobójczych wobec koronawirusów, zwłaszcza SARS-CoV-2, sposób jej otrzymywania i zastosowanie

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4244580A1 (de) 1992-12-31 1994-07-07 Galinski Erwin A Verfahren zur in vivo Gewinnung von Inhaltsstoffen aus Zellen
DE4342560A1 (de) * 1993-12-14 1995-06-22 Marbert Gmbh Ectoin und Ectoinderivate als Feuchtigkeitsspender in Kosmetikprodukten
NZ512383A (en) * 1998-12-22 2003-05-30 Univ North Carolina Use of osmotic agents in the treatment of airway diseases and for the delivery of airway drugs
ATE247981T1 (de) * 1999-06-12 2003-09-15 Bitop Ag Proteinenthaltende pharmazeutische zubereitung
DE10006578C2 (de) * 2000-02-14 2002-10-31 Bitop Ag Verwendung von kompatiblen Soluten als Inhibitoren des enzymatischen Abbaus von makromolekularen Biopolymeren
DE10065986A1 (de) 2000-12-21 2002-07-11 Bitop Gmbh Kompatible Solute als Stabilisatoren für Impfstoffe und Vakzine
DE10330243A1 (de) 2003-07-03 2005-01-20 bitop Aktiengesellschaft für biotechnische Optimierung Verwendung von aus extremophilen Bakterien gewonnenen Osmolyten zur Herstellung von Arzneimitteln zur äusserlichen Behandlung der Neurodermitis
DE10330768A1 (de) 2003-07-07 2005-02-24 bitop Aktiengesellschaft für biotechnische Optimierung Verwendung von aus extremophilen Bakterien gewonnenen Osmolyten zur Herstellung von inhalierbaren Arzneimitteln zur Prophylaxe und Behandlung pulmonaler und kardiovaskulärer Erkrankungen, sowie eines Osmolyte als Wirkstoffbestandteil enthaltende Inhalationsvorrichtung
DE102006056766A1 (de) 2006-12-01 2008-06-05 Bitop Ag Verwendung von kompatiblen Soluten
DE102007040615A1 (de) * 2007-08-27 2009-03-05 Bitop Ag Osmolyte zur Behandlung von allergisch oder viral bedingten Atemwegserkrankungen

Also Published As

Publication number Publication date
PL2753330T3 (pl) 2018-05-30
JP6396544B2 (ja) 2018-09-26
BR112014005414A2 (pt) 2017-04-04
EP2753330A1 (de) 2014-07-16
RU2648475C2 (ru) 2018-03-26
DE102011113059A1 (de) 2013-03-14
CN103857394A (zh) 2014-06-11
EP3287131A1 (de) 2018-02-28
IN2014CN02458A (enExample) 2015-08-07
ES2657907T3 (es) 2018-03-07
RU2014113906A (ru) 2015-10-20
ES2795879T3 (es) 2020-11-25
US20140315869A1 (en) 2014-10-23
CA2848010A1 (en) 2013-03-14
EP3287131B1 (de) 2020-03-04
WO2013034299A1 (de) 2013-03-14
PL3287131T3 (pl) 2020-10-19
JP2017197569A (ja) 2017-11-02
EP2753330B1 (de) 2017-11-08
JP2014526448A (ja) 2014-10-06

Similar Documents

Publication Publication Date Title
JP6396544B2 (ja) エクトインの治療的使用
JP6795574B2 (ja) Ｒｐｌ５５４を含む液体吸入製剤
AU2018201642B2 (en) Ciclesonide for the treatment of airway disease in horses
WO2019033122A1 (en) TREATMENT OF PULMONARY DISEASES USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS
EP4146202A1 (en) Method of treating a patient infected with a coronavirus with nezulcitinib
WO2022271604A1 (en) Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/l
EP3765059A1 (en) Methods of treating or preventing acute respiratory distress syndrome
JP2021191804A (ja) 二重ｐｉ３ｋデルタ‐ガンマキナーゼ阻害剤及びコルチコステロイドを含む治療方法及び組成物
JPWO2017209270A1 (ja) ２５−ヒドロキシコレステロール又はその類縁体コレステロールを有効成分として含有してなる、活性化されたｔ細胞及び／又はｂ細胞に選択的な細胞死誘導剤又は細胞死促進剤
JP2019532980A (ja) 皮膚症状を治療するためのチアゾールおよび副腎皮質ステロイドを含む併用療法
EP2808025B1 (en) Pharmaceutical composition and quasi-drug cosmetic using same
RU2013148786A (ru) Улучшенный состав суспензии кортикостероида для ингаляционного введения
US20180280338A1 (en) Compositions and methods for treating and preventing lung injury
JP2020515590A (ja) Ｈｉｆプロリルヒドロキシラーゼ活性の阻害剤としてのカンナビジオール誘導体
JPWO2012147705A1 (ja) トレハロースを含有する炎症性呼吸器疾患の治療剤
EP4501326A1 (en) Therapeutic agent for respiratory disease
CN115397433A (zh) 含有海藻糖或海藻糖衍生物的药物和鼻喷雾剂
NZ729419B2 (en) Method of treatment and compositions comprising a dual pi3k delta-gamma kinase inhibitor and a corticosteroid
HK1204556B (en) Pharmaceutical composition and quasi-drug cosmetic using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150907

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170707

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170822

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171024

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171122

R150 Certificate of patent or registration of utility model

Ref document number: 6250542

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250